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. In this Letter, we reported that mice lacking the catalytic subunit of PI(3)Kg on 129J backgrounds develop invasive colorectal tumours. We have observed this cancer phenotype in mouse lines derived from two different targeted embryonic stem-cell clones for at least two years. However, after backcrossing these mice onto a C57BL/6 background, we now find that the tumour phenotype has disappeared. Also, when we retargeted the allele in different ES cells using the same targeting construct, no tumours developed. Inactivation of PI(3)Kg in mice therefore does not in itself cause colon cancer, but may require additional factors-for example, the impaired immunity of p110g -/-mice may make them susceptible to tumours triggered by environmental and infectious agents 1 . Our finding that overexpression of p110g in different human colon-cancer cells results in decreased cell growth still stands, as does the frequent downregulation of p110g protein in colon-cancer patients (since independently confirmed 2 ). Some authors (Y.H., A.H., M.R., S.G. and T.W.M.) are not cosignatories to this statement. A In this Letter, the data for host strains WH8012 and WH8109 in Fig. 1 In this Letter it was reported that an amino-terminal CDKinhibitory domain of the Cdc6 replication protein was required for efficient mitotic exit, and that removal of this domain lethally blocked mitotic exit in cells lacking the Sic1 CDK inhibitor, demonstrating essential CDK-inhibitory control of CDK activity. However, Archambault et al. 1 have shown that viable mitotic-exit-competent strains lacking both CDK-inhibitors can be constructed, a finding that has also been confirmed by the authors. Archambault et al.
1 suggest that CDK-inhibitors are not required for mitotic exit in the wild-type cell cycle. However, A.C. 
